Full Press Release Details
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025.
ALXO
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
Key Takeaway: ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
Price reaction · baseline $0.4352 (2025-05-12 close) · hit after-hours · clean, no other ALXO news in the window
day 0 close · peak
+10.5%
day 1
+5.6%
day 3
+0.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)